TrialAntimicrobial agents and chemotherapy2025
Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants.
David Margolis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.